# Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia

> **NCT07422779** · NA · RECRUITING · sponsor: **Institute of Oncology Ljubljana** · enrollment: 100 (estimated)

## Conditions studied

- Metastatic Melanoma
- Skin Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT07422779
- **Lead sponsor:** Institute of Oncology Ljubljana
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-01
- **Primary completion:** 2027-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07422779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07422779, "Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07422779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*